ABSTRACT
Objective The gold-standard for the management of patients affected by large-surface third-degree burns is autologous skin graft. There is no way to accurately assess burned area size and predict the number of cells and the time necessary to produce a skin graft.
Materials and Methods When burns affect <40% total body surface area (TBSA), meshed skin samples harvested from non-affected donor sites can be used as grafts. In cases corresponding to burns affecting >40% TBSA), the donor site surfaces are insufficient. The alternative grafting strategy uses bioengineered skin substitutes that are generated using the own keratinocytes of the patient after ex vivo expansion. We developed a software for severe burn diagnosis and autologous skin substitute production.
Results We developed a software-assisted calculation of the required graft surface and keratinocyte numbers and the time to produce the graft needed, according to patient clinical characteristics. The software also offers assistance to estimate the Baux score, a method that links the severity of burn injuries and the prognosis for the patient.
Discussion Optimal setup of the bioengineering process involved determination of the required graft surface, adjustment of cell quantities, and control of the timing necessary for production. This could be determined and automated by this software. Accordingly, tools to assist the design of personalized protocols will contribute to care quality and cost limitation.
Conclusion This software provides a principle of assisted burned patient diagnose and skin substitute bioengineering process which development may facilitate the design of personalized protocols for skin regenerative cell therapies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There is no need to have an approval as all data presented here correspond to a fictious patient.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest: the author declares no conflicts of interest.
ABBREVIATIONS
- A
- Age
- API
- Application Programming Interface
- AT
- amplification time
- BCY
- biopsy cell yield (number of cells extracted from a biopsy cm2)
- BSA
- Body Surface Area
- BZ
- Biopsy Size
- GRC7
- Growth Rate of Cells in 7 days (average number of cells obtained from a single cell)
- GZ
- Graft Size
- H
- Height
- HTTP
- Hypertext Transfer Protocol
- FNC
- Final number of cells to seed per cm2 7 days before grafting
- STSG
- Split Thickness Skin Graft
- TBSA
- Total Body Surface Area
- TNCR
- Total Number of Cells Required
- WHO
- World Health Organization
- W
- Weight
- %TBSA
- Percentage of Total Body Surface Area burned
